@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw